The Cell and Gene Therapy Catapult (CGT Catapult) announced that it will be...
Researchers discover structure of anti-ageing hormone
Researchers at NYU School of Medicine have discovered the molecular structure of a hormone that controls the ageing process.
Breaking cancer’s drug addiction
Cancer cells can become addicted to the drugs designed to kill them, and now a group of scientists from the Netherlands Cancer Institute has discovered the underlying mechanism. Abi Millar finds out why cells die en masse when treatment is removed and how this could be exploited in a clinical setting.
Sanofi and Regeneron’s Kevzara faces competition in rheumatoid arthritis market
At the 36th annual J.P. Morgan Healthcare Conference, Sanofi and Regeneron discussed the anticipated success of Kevzara (sarilumab), an interleukin 6 (IL-6) inhibitor approved in 2017 for moderate to severely active rheumatoid arthritis (RA) patients with an inadequate response or intolerance to at least one disease-modifying anti-rheumatic drug (DMARD).
Batavia Biosciences joins project to develop new polio vaccine
Biopharmaceutical manufacturer Batavia Biosciences is joining an international consortium to sustain a polio-free world once the disease has been eradicated.
Patients with chronic pain and spasticity have a long history of pain that may extend over decades. This pain lies like an unendurable load on life and, for the person affected, this becomes an endless burden.
Could treating heart diseases with anti-inflammatories be the biggest breakthrough since statins?
A research team in the US has found that anti-inflammatory drugs could reduce the risk of heart attacks, independent of cholesterol. Elly Earls finds out why this is being hailed as the biggest breakthrough since the discovery of statins.
How Dupixent is establishing itself as the premier dermatology treatment
Dupixent (dupilumab) is currently the most successful biologic treatment for moderate-to-severe atopic dermatitis, developed by a joint venture between Regeneron Pharmaceuticals and Sanofi Genzyme.
Nanobiotix to conduct pancreatic cancer research with NBTXR3
French nanomedicine firm Nanobiotix has partnered with US-based Providence Cancer Institute to carry out pre-clinical research of its immunotherapeutic candidate NBTXR3 for pancreatic cancer.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.